RxDoctor Payments Data

Amineh El-Ghali

Family Medicine · Canoga Park, CANPI 1326543265

Payments from drug & device makers

$2,216in general payments, 2019–2025

Across 83 payments — averaging $26.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$784
  • GSK$264
  • Otsuka America Pharmaceutical, Inc.$229
  • Ironwood Pharmaceuticals, Inc$202
  • Medtronic$142
  • Bayer$122
  • plus $474 from 12 others

What the payments were for

  • Food & beverage$2,216100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,216 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$25,327
Medicare patients
119
Services billed
662

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$49,495
LinzessLinaclotide41$34,306
JanumetSitagliptin Phos/Metformin Hcl26$32,141
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$24,625
JanuviaSitagliptin Phosphate15$15,406
EliquisApixaban17$13,114
Diclofenac Sodium29$11,863
Icosapent Ethyl18$3,032
Azelastine Hcl61$1,446
Albuterol Sulfate HfaAlbuterol Sulfate48$1,276
Memantine Hcl ErMemantine Hcl11$1,224
Potassium Chloride13$869
Megestrol Acetate17$824
Triamcinolone Acetonide57$824
Gabapentin71$712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$104$49,49546 claims
MerckJanumet, Januvia$14$47,54741 claims
AbbVieLinzess$784$34,30641 claims
GSKTrelegy Ellipta$264$24,62533 claims
PfizerEliquis$21$13,11417 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$41956 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Canoga Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →